TECHNOLOGYAtlas Bio Raises $12.5 Million to Rethink How Drugs Are Tested
Swiss biotech startup Atlas Bio has raised $12.5 million to advance AI-powered simulations that help drug developers predict how treatments may affect patients before committing to costly clinical trials. The approach could improve early drug-development decisions, but its predictions still need rigorous validation against real-world clinical evidence.
